Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 606-616

  You, Shuo ^a,c   Li, Rui ^a   Park, Dongkyoo ^a   Xie, Maohua ^a   Sica, Gabriel L ^b   Cao, Ya ^c   Xiao, Zhi Qiang ^d   Deng, Xingming ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; NICLOSAMIDE; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN;

ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; LUNG CANCER; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

APOPTOSIS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; JANUS KINASE 2; LUNG NEOPLASMS; NICLOSAMIDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84896278080     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0608     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians 2013;63:11-30.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
3. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5.
4. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000;19:2474-88. (Pubitemid 30339203)
5. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-56. (Pubitemid 30339210)
6. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468-73. (Pubitemid 30339202)
7. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
8. Looyenga BD, Hutchings D, Cherni I, Kingsley C, Weiss GJ, Mackeigan JP. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma. PLoS ONE 2012;7:e30820.
9. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 2003;171:3863-71. (Pubitemid 37254592)
10. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005;4:1131-3. (Pubitemid 41365374)
11. Yin Z, Zhang Y, Li Y, Lv T, Liu J, Wang X. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem 2012;114:151-8.
12. Lateef M, Zargar SA, Khan AR, Nazir M, Shoukat A. Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide. Int J Infect Dis 2008;12:80-2. (Pubitemid 350299228)
13. Weinbach EC, Garbus J. Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature 1969;221:1016-8.
14. Ren XM, Duan L, He QA, Zhang Z, Zhou Y, Wu DH, et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. Acs Med Chem Lett 2010;1:454-9.
15. Merschjohann K, Steverding D. In vitro trypanocidal activity of the anti-helminthic drug niclosamide. Exp Parasitol 2008;118:637-40.
16. Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010;70:2516-27.
17. Ito T, Deng X, Carr B, May WS. Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem 1997;272:11671-3. (Pubitemid 27202724)
18. Lee YS, Oh JH, Yoon S, Kwon MS, Song CW, Kim KH, et al. Differential gene expression pro files of radioresistant non-small-cell lung cancer cell lines established by fractionated irradiation: tumor protein p53-inducible protein 3 confers sensitivity to ionizing radiation. Int J Radiat Oncol Biol Phys 2010;77:858-66.
19. Liu Y, Sun SY, Owonikoko TK, Sica GL, Curran WJ, Khuri FR, et al. Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Mol Cancer Ther 2012;11:45-56.
20. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro . Nat Protoc 2006;1:2315-9.
21. Deng X, Gao F, May WS Jr. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood 2003;102:3179-85. (Pubitemid 37314754)
22. Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res: an official journal of the American Association for Cancer Research 2009;15:150-9.
23. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81. (Pubitemid 40825512)
24. Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, et al. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011;17:710-20.
25. Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008;7:1952-8.
26. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105-15. (Pubitemid 29077388)
27. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao YX, Pestell RG, Albanese C, et al. Stat3 as an oncogene (vol 98, pg 295, 1998). Cell 1999;99.
28. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-44. (Pubitemid 32681546)
29. Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 2005;392:335-44. (Pubitemid 41796522)
30. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139-42. (Pubitemid 34496590)
31. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 2001;107:351-62.
32. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976-85. (Pubitemid 23267698)
33. Coate LE, Massey C, Hope A, Sacher A, Barrett K, Pierre A, et al. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol 2011;6:537-44.
34. Provencio M, Sanchez A, Garrido P, Valcarcel F. New molecular targeted therapies integrated with radiation therapy in lung cancer. Clinical Lung Cancer 2010;11:91-7.
35. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239-53.
36. Rosser CJ, Gaar M, Porvasnik S. Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? BMC Cancer 2009;9:225.
37. Su ZZ, Lebedeva IV, Sarkar D, Emdad L, Gupta P, Kitada S, et al. Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2. Oncogene 2006;25:2339-48.
38. Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res: an of ficial journal of the American Association for Cancer Research. 2005;11:8131-44.
39. Abdel Raheem AM, Hameed DA, ElGanainy EO, Mosad E, Abdelwanis ME, Kamel NA, et al. Can Bcl-XL expression predict the radio sensitivity of bilharzial-related squamous bladder carcinoma?Aprospective comparative study. BMC Cancer 2011;11:16.
40. Pan JX, Ding K, Wang CY. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer 2012;31:178-84.